Close

International: National Export Initiative

Biotechnology companies would be less likely to export their products into countries that do not provide meaningful IP and data protections

BIO Applauds Administration’s Progress in Brazilian Cotton Dispute

The Obama Administration has made substantial progress to avoid retaliatory measures in a long-running “cotton dispute” brought by Brazil against the United States.

BIO Welcomes EU Decision on Biotech Crops

The Biotechnology Industry Organization (BIO) applauded today’s announcement by the European Commission to authorize the cultivation of a biotech potato, as well as the commercialization of three varieties of biotech maize for food and feed uses and import and processing.

Letter, Identification of Countries involving the Special 301 provisions

BIO Members have a particular interest in encouraging uniform and robust intellectual property protection in all countries and regions of the world. As a general matter, BIO notes with concern recent trends in a number of countries that undermine the intellectual property protection essential to provide an enabling environment for innovative biotech companies.

BIO comments on National Trade Estimate Report on Foreign Trade Barriers

This letter is submitted by the Biotechnology Industry Organization (BIO) in response to the request for public comment with respect to the annual National Trade Estimate Report on Foreign Trade Barriers in the Federal Register on September 24, 2009.

Comments, 8th Meeting of the Convention on Biological Diversity (CBD) Ad Hoc Open-ended Working Group on Access and Benefit-Sharing

Comments, 8th Meeting of the Convention on Biological Diversity (CBD) Ad Hoc Open-ended Working Group on Access and Benefit-Sharing.

Letter, United Nations Framework Convention on Climate Change

U.S. Department of State

The Draft Guidance for Industry on Good Importer Practices

The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry on Good Importer Practices. This guidance provides a useful quality systems framework for importers across all FDA-regulated industries to promote the safety of imported products. Biotechnology companies are currently leading significant efforts to further enhance the safety and security of biopharmaceuticals at every step of the supply chain and we encourage the FDA to minimize the potential for divergence between this guidance and current drug and biologic Good Manufacturing Practices regulations.

Comments, Trans-Pacific Partnership Free Trade Agreements

Office of the U.S. Trade Representative

BIO Applauds Fifth Anniversary of the Biosafety Protocol

The Biosafety Protocol is an international environmental treaty under the United Nations Convention on Biological Diversity, which establishes rules and procedures for the international trade in certain agricultural biotechnology products.